C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients

References

• Mo D-C, Huang J-F, Luo P-H, et al. Combination therapy with immune checkpoint inhibitors in advanced renal cell carcinoma: a meta-analysis of randomized controlled trials. Clin Immunol. 2021;232:108876.
   PubMedGoogle Scholar
• Powles T, ESMO Guidelines Committee. Electronic address: [email protected] Recent eUpdate to the ESMO clinical practice guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer. Ann Oncol. 2021;32(3):422–423.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–1290.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813.
   PubMed Web of Science ®Google Scholar
• Harshman LC, Drake CG, Choueiri TK. PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. Cancer Immunol Res. 2014;2(12):1132–1141.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974–1982.
   PubMed Web of Science ®Google Scholar
• Ornstein MC, Garcia JA. Toxicity of checkpoint inhibition in advanced RCC: a systematic review. Kidney Cancer. 2017;1(2):133–141.
   PubMedGoogle Scholar
• Maher VE, Fernandes LL, Weinstock C, et al. Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody. J Clin Oncol. 2019;37(30):2730–2737.
   PubMed Web of Science ®Google Scholar
• Martini DJ, Goyal S, Liu Y, et al. Immune‐related adverse events as clinical biomarkers in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. The Oncologist. 2021;26(12):1017–1025.
   PubMed Web of Science ®Google Scholar
• Paderi A, Giorgione R, Giommoni E, et al. Association between immune related adverse events and outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Cancers. 2021;13(4):860.
   PubMed Web of Science ®Google Scholar
• Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunotherapy Cancer. 2019;7(1):306.
   PubMed Web of Science ®Google Scholar
• Du Clos TW. Function of C-reactive protein. Ann Med. 2000;32(4):274–278.
   PubMed Web of Science ®Google Scholar
• Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-Lymphocyte ratio in solid tumors: a systematic review and meta-Analysis. JNCI. 2014;106(6):dju124-dju.
   Google Scholar
• Bowen RC, Little NAB, Harmer JR, et al. Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis. Oncotarget. 2017;8(19):32171–32189.
   PubMedGoogle Scholar
• Ethier J-L, Desautels D, Templeton A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017;19(1):2.
   PubMed Web of Science ®Google Scholar
• Pilskog M, Beisland C, Akslen LA, et al. Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma. BMC Urol. 2017;17(1):74.
   PubMed Web of Science ®Google Scholar
• Takamatsu K, Mizuno R, Omura M, et al. Prognostic value of baseline serum C-reactive protein level in intermediate-risk group patients with metastatic renal-cell carcinoma treated by first-line vascular endothelial growth factor–targeted therapy. Clin Genitourin Cancer. 2018;16(4):e927–e33.
   PubMed Web of Science ®Google Scholar
• Laino AS, Woods D, Vassallo M, et al. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J Immunother Cancer. 2020;8(1):e000842.
   PubMed Web of Science ®Google Scholar
• Adachi Y, Tamiya A, Taniguchi Y, et al. Predictive factors for progression‐free survival in non‐small cell lung cancer patients receiving nivolumab based on performance status. Cancer Med. 2020;9(4):1383–1391.
   PubMed Web of Science ®Google Scholar
• Riedl JM, Barth DA, Brueckl WM, et al. C-Reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: a bi-center study. Cancers. 2020;12(8):2319.
   PubMed Web of Science ®Google Scholar
• Bilen MA, Dutcher GMA, Liu Y, et al. Association Between pretreatment neutrophil-to-lymphocyte ratio and outcome of patients with metastatic renal-cell carcinoma treated with nivolumab. Clinical Genitourinary Cancer. 2018;16(3):e563–e75.
   PubMed Web of Science ®Google Scholar
• Ishihara H, Tachibana H, Takagi T, et al. Predictive impact of peripheral blood markers and C-Reactive protein in nivolumab therapy for metastatic renal cell carcinoma. Target Oncol. 2019;14(4):453–463.
   PubMed Web of Science ®Google Scholar
• Roussel E, Kinget L, Verbiest A, et al. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab. Urol Oncol. 2021;39(4):239.e17–e25.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Terakawa T, Furukawa J, et al. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab. Int J Clin Oncol. 2020;25(1):135–144.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Robbins PB, Powles T, et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN renal 101 trial. Nat Med. 2020;26(11):1733–1741.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer. 2020;8(2):e000891.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–1755.
   PubMed Web of Science ®Google Scholar
• Yoest J. Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. Immunotargets Ther. 2017;6:73–82.
   PubMed Web of Science ®Google Scholar
• Indini A, Di Guardo L, Cimminiello C, et al. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. J Cancer Res Clin Oncol. 2019;145(2):511–521.
   PubMed Web of Science ®Google Scholar
• Ricciuti B, Genova C, De Giglio A, et al. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol. 2019;145(2):479–485.
   PubMed Web of Science ®Google Scholar
• Teulings H-E, Limpens J, Jansen SN, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33(7):773–781.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Fishman MN, Escudier B, et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. Clinical Cancer Research. 2016;22(22):5461–5471.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867.
   PubMed Web of Science ®Google Scholar
• Heng DYC, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated With vascular endothelial growth factor–targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–5799.
   PubMed Web of Science ®Google Scholar